Artal Group’s Definium Therapeutics DFTX Stock Holding History

Artal Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,007,875	Closed	-$7.27M	–	58
2024 Q2	$7.27M	Buy	+1,007,875	New	+$8.81M	0.19%	50

Other funds holding DFTX

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artal Group's DFTX Position: Q3 2024 in Review

Artal Group sold out of Definium Therapeutics (DFTX) in Q3 2024, closing a stake of 1,007,875 shares — an estimated $7.27M sold.

Artal Group first reported a position in DFTX in Q2 2024 and held it in 1 quarter. The position peaked at $7.27M in Q2 2024. 157 funds tracked by Wall St. Rank hold DFTX as of Q3 2024.

Artal Group reported no remaining Definium Therapeutics position as of Q3 2024 after selling out during the quarter.
Artal Group sold 1,007,875 Definium Therapeutics shares in Q3 2024, an estimated $7.27M.
Artal Group first reported a position in Definium Therapeutics in Q2 2024 and held it in 1 quarter.
Artal Group's Definium Therapeutics position peaked at $7.27M in Q2 2024.
157 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.